跳至主要内容
临床试验/NCT02872038
NCT02872038已完成4 期

A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis

Chulalongkorn University1 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
154
试验地点
1
主要终点
Primary response rate

研究概览

简要总结

The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.

详细描述

The International Society of Peritoneal Dialysis (ISPD) guideline suggest to use combination of antibiotics to cover both of gram positive and gram negative bacteria. The usual regimen in Thailand is cefazolin plus ceftazidime. Despite combination therapy, monotherapy is also possible for empirical treatment of CAPD-associated peritonitis since it helps to lowering staff burden and lowering risk of contamination. Cefepime could be an ideal antibiotic for empirical treatment of CAPD-associated peritonitis as it is an extended-spectrum cephalosporin, forth generation, covering most of gram positive and gram negative bacteria. In addition, cefepime is not broken down by many of the beta-lactamases and less beta-lactamases inducer. This study aims to prove the noninferiority of cefepime monotherapy to cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis.

CAPD-associated peritonitis was diagnosed by at least two of the following criteria: abdominal pain or cloudy peritoneal dialysis fluid (PDF); PDF white cell count > 100/μL with > 50% polymorphonuclear(PMN); and positive gram stain or culture. The patients were randomized into two groups by block of four randomization, sealed envelope. Treatment group was treated with intraperitoneal (IP) cefepime 1 g loading following by maintenance dose 250 mg IP all exchanges. Control group was treated with cefazolin 1 g IP loading and ceftazidime 1 g IP loading following by maintenance dose of cefazolin and ceftazidime 250 mg IP all exchanges. If a patient had residual urine ≥ 100 ml/day, dose of antibiotics would be increased by 25%.

On the first day, the initial blood tests for complete blood count, electrolyte, BUN, creatinine, calcium, phosphate and magnesium were obtained. While peritoneal dialysis fluid were collected using two methods of bacterial culture, both of centrifugation of 50 ml peritoneal dialysis fluid at 3,000 g for 15 minutes and bedside 5-10 ml of peritoneal dialysis fluid inoculated into the blood culture bottles. PDF gram stain and bacterial culture were done. The patients were followed on day 3, 5, 10, 14, 21 and 28 days after the completion of antibiotic course. If clinical improved, the antibiotics would be adjusted according to the culture result and sensitivity after day 5. If clinical not improved the antibiotics would be step up and Tenckhoff catheter removal was considered (on any day of treatment). The patients were treated at least 14 days or 21 days depend on the culture result (as the recommendation of ISPD guideline 2010).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age more than 18 years
  • CAPD initiation more than 4 weeks

排除标准

  • Exit site or tunnel infection
  • Previous CAPD-associated peritonitis treatment within 4 weeks
  • Drug allergy to cephalosporin
  • Tenckhoff catheter malfunction
  • Hospitalization more than 48 hours
  • Fungal or Mycobacterium infection
  • Suspected secondary peritonitis
  • Concomitant antibiotics.

研究组 & 干预措施

Treatment

Experimental

Cefepime intraperitoneal continuous dosing

干预措施: Cefepime (Drug)

Control

Active Comparator

Cefazolin plus Ceftazidime intraperitoneal continuous dosing

干预措施: Cefazolin plus Ceftazidime (Drug)

结局指标

主要结局

Primary response rate

时间窗: day 10 of treatment

Resolution of clinical peritonitis and peritoneal dialysis fluid WBC \< 100 /μL with PMN \< 50% at day 10

次要结局

  • Initial response rate(day 5 of treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thidarat Kitrungphaiboon, MD

Fellow of Nephrology

Chulalongkorn University

研究点 (1)

Loading locations...

相似试验